About US
Contact us
-
DFE Pharma Customer Value Management Survey: coming soonDear customer Your experience with DFE Pharma is something we are always looking to improve. The DFE Pharma biennialCustomer Value Management Survey is a key source of insights on how we’re performin2014/6/4
-
Adaptimmune and GSK enter into collaboration for NY-ESO-1 clinical cancer programmeUK-based Adaptimmune has entered into a strategic cancer immunotherapy collaboration with GlaxoSmithKline (GSK) to develop and commercialise Adaptimmune's NY-ESO-1 clinical cancer programme. Under th2014/6/4
-
Eisai's antiemetic agent Aloxi gets FDA approval to treat childrenJapan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomitin2014/6/4
-
Newron submits new drug application to FDA for Parkinson's disease treatmentNewron Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for safinamide, which is being developed as an add-on therapy to dopamine agonists or to2014/6/3
-
Eisai's antiemetic agent Aloxi gets FDA approval to treat childrenJapan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomitin2014/6/3
-
Bristol-Myers Squibb collaborates with CytomX on immuno-oncology targetsBristol-Myers Squibb has signed a worldwide research collaboration and licence agreement with CytomX Therapeutics to discover, develop and commercialise new therapies using CytomX's Probody platform a2014/5/30
-
Celerion and KDDF sign agreement to advance drug discovery in South KoreaUS-based Celerion and the Korean Drug Development Fund (KDDF) have signed a collaboration agreement aimed at strengthening early phase clinical research in South Korea. A memorandum of understanding2014/5/30
-
Advaxis receives orphan drug designation for osteosarcoma immunotherapyAdvaxis has received orphan drug designation (ODD) from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its ADXS-cHER2, indicated for treatment of osteosarcoma.2014/5/29
-
EMA adopts positive opinion on Octapharma’s haemophilia A drug NuwiqThe European Medicines Agency (EMA) has given a positive opinion towards Octapharma's human cell line recombinant human FVIII, Nuwiq, recommending the granting of marketing authorisation for treatment2014/5/29
-
Teva and Active Biotech to Continue with the Development of Nerventra (Laquinimod) for MS Following Confirmation of CHMP OpinionTeva Pharmaceutical Industries Ltdand Active Biotechhave announced that the Committee for Medicinal Products for Human Use (CHMP) confirmed its 23 January 2014 opinion to recommend against approval fo2014/5/28